Monday, November 4, 2024
HomeTagsRrMM

rrMM

Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma

Data Describing Activity of P-BCMA-ALLO1 in BCMA-Experienced Patients to be Presented at Upcoming AACR Meeting Poseida Therapeutics, Inc., a clinical-stage cell and gene therapy company...

Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program

Arcellx, Inc., a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, announced that...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics